New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
16:07 EDTGILDGilead reports Q4 EPS 50c, consensus 48c
Reports Q4 revenue $2.59B, consensus $2.43B.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
July 29, 2015
09:13 EDTGILDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Buffalo Wild Wings (BWLD), up 11.4%... Panera Bread (PNRA), up 5.9%... Sonus Networks (SONS), up 7.2%... Gilead Sciences (GILD), up 3.6%... U.S. Steel (X), up 3.3%... Synchronoss (SNCR), up 2.8%. ALSO HIGHER: Cytec Industries (CYT), up 26.7% after being acquired by Solvay (SVYZY)... MagneGas (MNGA), up 7.8% after receiving multiple orders... AK Steel (AKS), up 5.2% after being upgraded to Outperform from Neutral at Macquarie. DOWN AFTER EARNINGS: Yelp (YELP), down 23.6%... VASCO Data Security (VDSI), down 13.3%... Tableau Software (DATA), down 16%... Twitter (TWTR), down 11.4%... Akamai Technologies (AKAM), down 7.9%.
07:25 EDTGILDGilead price target raised to $133 from $116 at JPMorgan
Subscribe for More Information
06:23 EDTGILDGilead price target raised to $135 from $125 at Deutsche Bank
Subscribe for More Information
06:16 EDTGILDGilead price target raised to $134 from $131 at Piper Jaffray
Subscribe for More Information
July 28, 2015
16:08 EDTGILDGilead up almost 4% following better than expected Q2 results
Subscribe for More Information
16:05 EDTGILDGilead narrows FY15 adj product gross margin view to 88%-90% from 87%-90%
16:04 EDTGILDGilead reports Q2 antiviral product sales increased to $7.6B
Subscribe for More Information
16:03 EDTGILDGilead reports Q1 total product sales $8.1B
Total product sales for the second quarter of were $8.1B compared to $6.4B for the second quarter of 2014. Product sales in the U.S. were $5.6B compared to $4.8B for the second quarter of 2014. In Europe, product sales were $2B compared to $1.3B for the same period in 2014.
16:02 EDTGILDGilead raises FY15 net product sales view to $29B-$30B from $28B-$29B
Subscribe for More Information
16:01 EDTGILDGilead reports Q2 adjusted EPS $3.15, consensus $2.71
Subscribe for More Information
15:47 EDTGILDGilead July weekly 112 straddle priced for 6% movement
Subscribe for More Information
15:21 EDTGILDNotable companies reporting after market close
Subscribe for More Information
13:39 EDTGILDGilead technical notes before results
Subscribe for More Information
11:42 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
July 27, 2015
11:57 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
08:42 EDTGILDGilead July weekly volatility increases into Q2 and outlook
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; CRM GILD
Subscribe for More Information
July 24, 2015
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use